<DOC>
	<DOCNO>NCT00517543</DOCNO>
	<brief_summary>This study conduct measure amount study drug blood receive different type tablet four study visit .</brief_summary>
	<brief_title>A Study Examine Effect Particle Size Bioequivalence Bioavailability</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Healthy adult male females 18 60 year age , inclusive . Whether subject `` healthy '' determine responsible physician , base medical evaluation include history , physical examination , laboratory test , cardiac monitoring . To eligible , female subject must negative pregnancy test ( i.e . serum hCG test ) : 1. nonchildbearing potential ( i.e . physiologically incapable become pregnant ) . This include premenopausal female document ( medical report verification ) hysterectomy double oophorectomy postmenopausal define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL 6 week postsurgical bilateral oophorectomy without hysterectomy , document hysterectomy tubal ligation sufficient . 2. childbearing potential agrees commit two protocolapproved method contraception , use consistently accordance product label instruction physician ( list Appendix 3 ) . Male subject must agree abstain use condom sexual intercourse pregnant lactating female ; use condom/spermicide , addition female partner use another form contraception , IUD , diaphragm spermicide , oral contraceptive , inject able progesterone , sub dermal implant engage sexual intercourse female partner could become pregnant . This criterion must follow time first dose study medication completion follow procedure . Body weight &gt; / 50 kg ( 110 pound ) men &gt; / 45 kg ( 99 pound ) woman body mass index ( BMI ) 19 31 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) bilirubin within reference range screening . Signed date write informed consent prior admission study . The subject able understand comply protocol requirement , instruction protocolstated restriction Any clinically relevant abnormality identify screen medical assessment , laboratory examination , ECG ( 12 lead ) judge Investigator /or GSK medical monitor potentially introduce additional risk factor and/or interfere study procedure . Significant cardiac , pulmonary , metabolic , renal , hepatic , neurological , psychiatric , gastrointestinal condition opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial . History Gilbert 's syndrome . Elevated blood pressure history elevate blood pressure consider clinically significant Investigator . History increase liver function test [ alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) 1.5 x upper limit normal ( UNL ) past 6 month . History alcohol/drug abuse dependence within 12 month study . The subject positive prestudy drug alcohol screen . Positive Hepatitis C antibody , Hepatitis B surface antigen HIV . History regular alcohol consumption average &gt; 7 drinks/week woman &gt; 14 drinks/week men . One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 mL ) wine ; 12 ounce ( 360 mL ) beer ; 1.5 ounce ( 45 mL ) 80 proof distil spirit within 6 month screen . Urinary cotinine level indicative smoking . History regular use tobacco nicotinecontaining product within 6 month prior screen . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John'sWort , kava , ephedra ( huang ) , gingko biloba , DHEA , yohimbe , saw palmetto , ginseng red yeast rice ) within 7 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . Where participation study would result donation blood excess 500 mL within 56day period . Exposure four new chemical entity within 12 month prior first dose day . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) prior dose . Female subject nursing , pregnant , plan become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>inflammation</keyword>
</DOC>